Clinical trial · Interventional
Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer
A Multicentre Feasibility Study of Online Adaptive Image Guided Radiotherapy for Muscle Invasive Bladder Cancer
NCT01142102CI-TRIAL-00025602BOLARTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The principal objective of the trial is to test the hypothesis that Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer is feasible across multiple Radiation Oncology departments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- Radiation Therapy
- interventionNames
- Radiation: Radiation Therapy
Primary outcomes (1)
- measure
- Compliance with Online Adaptive Radiation Therapy process
- timeFrame
- From the start date of radiotherapy to the last day of radiotherapy treatment (approxiamately 6 weeks and 2 days)
- description
- A patient is considered to be compliant if that patient completes treatment without experiencing a major protocol deviation
Secondary outcomes (6)
- measure
- Pattern of failure and competing risks analysis
- timeFrame
- From date of enrolment, every three months after RT untill 24 months, then 6 monthly until the end of the trial
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older * Has provided written Informed Consent for participation in this trial * Histologically confirmed muscle invasive bladder cancer. * Transitional cell, squamous cell, adenocarcinoma or mixed histology. Stage T2-4 N0 M0. * An ECOG performance status score of 2 or less (see appendices). * Life expectancy greater than 6 months. * Considered suitable for radical radiotherapy. * Participants capable of childbearing are using adequate contraception. * Radiotherapy must be able to be commenced within 12 weeks of surgery. * Available for follow up. Exclusion Criteria: * Women who are pregnant or lactating. * Previous pelvic radiotherapy * Previous cystectomy * A small contracted bladder * Unilateral or bilateral hip replacement * Small cell histology * Clinical or radiological evidence of nodal or distant metastases * Presence of indwelling urinary catheter
References
Publications (0)
Data not yet available
No reference posted for this study.